^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HR positive

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    2099; 5241
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Laura Huppert, MD, BA | Trial completion date: Jun 2029 --> Sep 2029 | Trial primary completion date: Jun 2029 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HR negative
    |
    anvatabart opadotin (JNJ-0683)
    1d
    ASSET: Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, University of Kansas Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • PGR positive
    |
    Piqray (alpelisib) • Trodelvy (sacituzumab govitecan-hziy)
    2d
    Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival. (PubMed, Oncol Res)
    In the 62 subjects administered with just paclitaxel, no significant differences in PFS (p = 0.820) or OS (p = 0.143) were observed between favorable and unfavorable genetic profiles. The MDR analysis of VEGF-A rs833061 and VEGFR-2 rs1870377 genotypes can detect a subgroup of bevacizumab-administered+ metastatic breast cancer patients with improved PFS and OS.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    HR positive
    |
    Avastin (bevacizumab) • paclitaxel
    2d
    CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. (PubMed, Lancet Oncol)
    CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed.
    Clinical • P3 data • Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • AiRuiKang (dalpiciclib)
    2d
    From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer. (PubMed, Breast)
    KAT inhibition has shown potential to modulate oncogenic signaling and sensitize tumor cells to existing therapies, offering a complementary avenue for overcoming resistance. This review focuses on emerging cell cycle-centric mechanisms of resistance to CDK4/6 inhibitors and highlights innovative therapeutic strategies aimed at improving outcomes in HR+/HER2- mBC.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CDK2 (Cyclin-dependent kinase 2)
    |
    HR positive • HER-2 negative • EGFR positive
    2d
    ETHAN - ET for Male BC (clinicaltrials.gov)
    P2, N=60, Recruiting, Jose Pablo Leone | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)
    3d
    BREAKER-101: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=392, Recruiting, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | N=91 --> 392
    Enrollment change • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 positive • HR positive • HER-2 negative • PIK3CA mutation • HR positive + HER-2 negative
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • 5-fluorouracil • Kisqali (ribociclib) • fulvestrant • leucovorin calcium
    3d
    BNT326-01: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=980, Recruiting, BioNTech SE | N=329 --> 980
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • ALK rearrangement • PD-L1 expression + HER-2 overexpression • HER-2 negative + HR negative
    |
    itraconazole • pumitamig (BNT327) • BNT326
    3d
    Magnetic resonance imaging as a non-invasive breast cancer tool - the relevance of breast edema score: A retrospective study. (PubMed, World J Radiol)
    The presence and severity of MRI-based breast edema score have been found to correlate with aggressive molecular subtypes, underscoring the potential role of BES in prognostic stratification and guiding tailored treatment strategies.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • EGFR positive
    3d
    Case Report: Rare gastric and bone metastases after early endocrine therapy discontinuation in hormone receptor-positive breast cancer: lessons and therapeutic insights. (PubMed, Front Oncol)
    She received first-line endocrine therapy (letrozole+ribociclib+goserelin) combined with denosumab. Breast cancer gastric metastasis diagnosis relies on medical history, gastroscopy, and immunohistochemistry (GATA3+, CK7+, CK20-). The combination regimen yielded favorable efficacy, providing clinical reference for similar rare cases.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • GATA3 (GATA binding protein 3)
    |
    HR positive
    |
    Kisqali (ribociclib) • letrozole • Prolia (denosumab) • goserelin acetate
    3d
    EAY131-Y: Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    Truqap (capivasertib)